Reaktion #2146687

ord-9479d13a8d1746ebbe026f8062d709fe

Reaktionsgleichung

O
water
COc1ccc2nc(-c3ccc(O)cc3)cn2c1
2-(4′-hydroxyphenyl)-6-methoxyimidazo[1,2-a]pyridine
O=C([O-])[O-].[K+].[K+]
potassium carbonate
FCCCBr
1-bromo-3-fluoropropane
COc1ccc2nc(-c3ccc(OCCCF)cc3)cn2c1
2-[4′-(3″-fluoropropoxy)phenyl]-6-methoxyimidazo[1,2-a]pyridine
Ausbeute 63.0%

Lösungsmittel

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    Sonstigeto remove moisture
  2. 2
    workup.DISSOLUTIONwas dissolved in 10 L of N,N-dimethylformamide
  3. 3
    SonstigeAfter the completion of the reaction
  4. 4
    Extraktionextracted three times with chloroform
  5. 5
    WaschenThe combined chloroform layer was washed once with water and once with a saturated sodium chloride solution
  6. 6
    Trocknendried over anhydrous sodium sulfate
  7. 7
    Filtrationfiltered
  8. 8
    Einengenconcentrated
  9. 9
    SonstigeThe resulting crude product was purified by recycle preparative HPLC (HPLC apparatus

Vorschrift

242 mg (corresponding to 1.0 mmol) of 2-(4′-hydroxyphenyl)-6-methoxyimidazo[1,2-a]pyridine that was sufficiently dried to remove moisture was dissolved in 10 L of N,N-dimethylformamide, and 418 mg (corresponding to 3.0 mmol) of potassium carbonate was added thereto. The mixture was supplemented with 140 μL (corresponding to 1.5 mmol) of 1-bromo-3-fluoropropane, and then was stirred at room temperature for 18 hours. After the completion of the reaction, the reaction solution was poured into water and extracted three times with chloroform. The combined chloroform layer was washed once with water and once with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered and concentrated. The resulting crude product was purified by recycle preparative HPLC (HPLC apparatus: LC-908 (under trade name: manufactured by Japan Analytical Industry Co., Ltd.); column: two JAIGEL 2H (under trade name; manufactured by Japan Analytical Industry Co., Ltd.) connected together; mobile phase: chloroform), to obtain 189 mg (corresponding to 0.63 mmol) of 2-[4′-(3″-fluoropropoxy)phenyl]-6-methoxyimidazo[1,2-a]pyridine (hereinafter referred to as Compound 1) (FIG. 2, Step 6).

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08277777B2uspto-grants-2012_10